In experimental conditions inducing graft-versus-host disease (GVHD), in which lethally irradiated (BALB/c X C57BL/6)Fl mice received mixtures of BM and spleen cells from C57BL/6 donors, rhlL-6 was found to enhance GVHD manifestations. No consistent enhancement of T-cell in vitro proliferative responses to allogeneic spleen cells or T-and B-cell-dependent mitogens were seen in the splenocytes obtained from recipients of syngeneic or semiallogeneic BMT. Our data suggest that rhlL-6 may be useful in BMT procedures to enhance thrombopoiesis and hematologic recovery, as well as to increase overall survival rates. In addition, the potentiation of GVHD, which is considered to correlate with graft-versus-leukemia effects, may be of interest in enhancing GVHD-dependent antitumor effects in protocols combining radiochemotherapy with BMT. GM-CSF, produce multilineage c~lonies.~.' The interpretation of such experiments may be (l) that IL-6 promotes resting cells to enter cell cycling5 and/or ( 2 ) that IL-6 primes stem cells to respond to the hematopoietic growth factor^,^ explaining the synergism between IL-6 and IL-3, GM-CSF, or M-CSF in the formation of granulocytic, monocytic, erythroid, and megakaryocytic c o l~n i e s .~,~~~"~ However, IL-6 has also marked effects at later stages of myeloid cell development, allowing preformed murine blast colonies to differentiate into granulocytes and macrophages.'' Indeed, the myeloid differentiation inducer activity MGI-2 was identified as murine IL-6.I2 Alone or in combination with other cytokines, IL-6 promotes the terminal differentiation of murine and human myeloid leukemic cells.'2-'6 IL-6 is also a differentiation factor for megakaryocytes, promoting increment in size and ploidy17 and mediating apparently the effect of IL-3 on these cells.'* In vivo administration of IL-6 to normal and irradiated mice produces an increase in BM CFU cells and in peripheral blood neutrophils and platel e t~, '~-~' with the platelet increase being dominant in normal or irradiated primates treated with IL-6. [22] [23] In view of these multiple effects on hematopoietic cells, which may affect early stem cells as well as later stages of differentiation, IL-6 is of potential interest in clinical applications of BMT. However, IL-6 is a pleiotropic factor that acts on other cell types, inducing acute-phase proteins in hepatocytes, promoting Ig secretion in mature B cells and cytotoxic activities in T ~e l l s .~.~~ IL-6 stimulates pituitary hormone release25 and, in vivo, synergizes with IL-1 for adrenocorticotropic hormone (ACTH) release.26 IL-6 seems to have complex connections with the effects of IL-1 and tumor necrosis factor (TNF) on the modulation of ionizing radiation damage, whereas exogenous IL-6 by itself sensitizes mice to radiation lethality.27 When administered with IL-1, IL-6 enhances radioprotection. Judging by data from antibody-mediated blocking experiments, IL-6 appears to be essential, along with IL-1 and TNF, for radioresistance of mice.** Because of these multiple effects, the overall benefit of IL-6 administration on hematologic and immunologic parameters as well as on survival in BMT procedures after myeloablative irradiation needed to be carefully investigated. One study of syngeneic BMT in mice has indicated that recombinant (Escherichia coli) human IL-6 (rhIL-6) can improve survival and accelerate recovery of white blood cell (WBC) counts, neutrophils, and monocytes.29 In the present study, we report that, in both syngeneic and semiallogeneic BMT in mice, recombinant glycosylated hIL-6 (Chinese hamster ovary [CHO]) produces a marked improvement in survival rates that cannot be explained by radioprotection, and increases the recovery of platelets as well as the recovery of WBC. We also investigated the effects of rhIL-6 in semiallogeneic BMT, on long-term engraftment, and on graft-versus-host disease (GVHD).
MATERIALS AND METHODS
Mice. Male and female BALB/c, C57BL/6, and (BALB/c X C57BL/6) mice (FI), aged 2 to 4 months, were bred locally at the animal facility and kept in standard conditions, without isolation, with food and acidified water (pH 2.7) being given ad libitum.
rhIL-6. rhIL-6 (Ares-Serono; InterPharm, Nes-Ziona, Israel) was produced from C H 0 cells prepared and purified as described." The specific activity was 1.5 X IO7 reference units/mg protein, as determined in a plasmacytoma growth assay in comparison to standard 88/5 14 (National Institute for Biological Standards and Control, Potters Bar, UK). Endotoxin concentration was less than 0.1 ng endotoxin/mg protein. rhIL-6 (0.1 mg/mL) was diluted in phosphate-buffered saline (PBS) supplemented with 5% human serum albumin and administered subcutaneously once or twice daily as indicated.
BMT. BALB/c and F1 recipients were exposed to total body irradiation (TBI) with no anesthesia using a Phillips X-Ray Unit (20 A, 175 kv) with Cu 0.2 mm filter at a source-to-skin distance of 50 cm and a dose rate of 100 cGy/minute. TB1 doses of 550 cGy were sublethal in BALB/c mice. In most experiments, TB1 doses of 600 cGy proved 100% lethal without marrow reconstitution. However, the minimal lethal TB1 dose that permitted engraftment of semiallogeneic cells was 625 cGy. Therefore, doses from 600 to 650 cGy were chosen for the different BMT experiments in BALB/c mice. For measure of chimerism, a low and a high dose were compared (600 to 700 cGy). Syngeneic (BALB/c, H-2d), semiallogeneic (FI, H-2'Id), or allogeneic (C57BL/6, H-2') BM cells were prepared by flushing the shafts ofthe humera and femura bones using a 25-gauge needle with RPMI 1640 (Biological Industries, Kibutz Beth Ha'emek, Israel). BM cells were infused in 0.25 mL medium into the lateral tail vein of mice 20 hours after TBI.
Total WBC count and platelet count were monitored by puncturing the retro-orbital vein plexus with heparinized glass capillaries 8 to I4 days after BMT, as indicated.
Induction of GVHD. F1 mice recipients, which are more radioresistant than BALB/c, were exposed to 750 cGy TB1 and were infused 20 hours later with 1 to 1.5 X 1 O7 BM cells enriched with 20% to 50% spleen cells both from C57BL/6 donors. The T-cell content of the BM and spleen cell suspensions was, respectively, 7% and 35%, as determined by fluorescence-activated cell sorter (FACS) analysis. Parameters ofGVHD that were observed included subjective clinical observations (diarrhea and ruffled fur), as well as daily evaluation of body weight and survival.
Measure of chimerism. Peripheral blood lymphocytes (PBL) from BALB/c recipients were separated over a ficoll-hypaque gradient 6 weeks after engraftment with F1 BM cells. After lysis of residual red blood cells by ammonium chloride, the cells were suspended in RPMI with 5% fetal calfserum (FCS; GIBCO, Grand Island, NY) and phenotyped using anti-C57BL/6 antiserum prepared by grafting C57BL/6 skin to normal BALB/c mice, followed by three successive immunizations with C57BL/6 spleen cells at 2-week intervals. Rabbit serum adsorbed on normal spleen cells for 30 minutes on ice was used as a source of complement. Both antiserum and complement were kept at -70'C until use. Engraftment of donor cells was analyzed by comparing PBL viability after treatment with antiserum and complement compared with complement alone in chimeras, using PBL from BALB/c (0% killing) and C57BL/6 and F1 mice (100% killing) as controls. Cells (2 X 106/mL) in 10 pL were incubated in microplates with antiserum for 30 minutes at room temperature and a 1.5 dilution of complement was added for 45 minutes at 37°C in a 5% CO2 incubator. After centrifugation and washing, 15 pL of trypan blue was added to each well and the percentage of killed cells in PBL from tested chimeras relative to that in PBL from C57BL/6 controls was calculated.
Mixed lymphocyte reaction (MLR).
One-way MLR was performed by mixing 0.5 X IO6 spleen cells from BALB/c recipients of syngeneic BMT with IO6 irradiated (3,000 cGy) C57BL/6 spleen cells or irradiated syngeneic spleen cells as control. Cultures in 0.2 mL U-shaped 96-well microplates (Costar, Cambridge, MA) were performed in 0.2 mL RPMI I640 medium with 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 pumL streptomycin, 10% FCS, and 5 X mmol/L 2-mercaptoethanol for 3 days at 37°C in a humidified 5% CO2 air incubator. 'H-thymidine (54 Ci/mmol, 1 pC/well) was added for 20 hours, cells were collected in a Titertek Harvester on fiberglass filters and dried, and radioactivity was measured by liquid scintillation. The delta cpm (cpm in allogeneic MLR minus cpm in syngeneic MLR control) was first calculated and the immunologic reconstitution was expressed as the percentage of delta cpm with spleen cells obtained from BMT recipients relative to the delta cpm with cells obtained from healthy control mice.
ProlifPrative responses to mitogens. Spleen cells (2 X io5) from BALB/c recipients were incubated in 0.2 mL flat-bottom 96-well microplates as described above but with IO pg/mL Concanavalin A (ConA; Sigma, St Louis, MO), I pdmL phytohemagglutinin (PHA; Wellcome Labs, Beckenham, UK), or 50 pg/mL lipopolysaccharide (LPS; Difco Labs, Detroit, MI). After 3 days, 'H-thymidine incorporation was measured and the delta cpm of the mitogen-stimulated cells was expressed as a percentage of the delta cpm measured using spleen cells from normal mice.
Statistical evaluation. The Mann-Whitney t-test was used for the effects of rIL-6 on peripheral blood cell counts and the paired ttest was used to evaluate the changes in body weight during GVHD at specific days. The significance of Kaplan-Meier survival curves was analyzed by both the generalized Wilcoxon test and the logrank t e~t~' .~' using the SAS lifetest software.
RESULTS
Effect of rhIL-6 on hematopoietic reconstitution after syngeneic BMT. The effect of daily subcutaneous administration of 10 pg rhIL-6 for 10 days starting 1 day after BMT was investigated in BALB/c mice. From a total of 184 mice exposed to lethal TB1 of 600 cGy, four groups were inoculated with syngeneic BM cells at doses of either 5 X lo4 (32 mice), lo5, 5 X lo5, or lo6 (44 mice in each group), with the remaining 20 mice receiving no BM cells and serving as irradiation controls. Half of the mice in each group received the rhIL-6 injections and half received a similar schedule of PBS injections as controls. All unreconstituted, irradiated controls died within 28 days (median survival, 12 days). In the groups reconstituted with 0.5 or 1 X lo5 BM cells, the control mice showed partial survival (Fig l A and B ). For these two groups, treatment with rhIL-6 for 10 days post-BMT produced a significant improvement of actuarial sur- viva1 rates (difference significant at P = .02 by log-rank test and generalized Wilcoxon test). At 50 days, actual survival was 65.3% -+ 4% for the IL-6-treated mice versus 36.9% k 0.7% for the control mice of these two groups (P < .01). An increase in survival in relation to the BM cell dose is shown in Fig 1D. In this experimental setting, mice receiving 5 to 10 X lo5 BM cells showed long-term survival of approximately 90%, regardless of treatment with rhIL-6 (Fig 1C and  D) . In a subset of this experiment, WBC counts were measured at days +8 and + 14 after BMT. In the groups receiving 0.5 to 1 X lo5 BM cells, the WBC levels were still much below normal values at 14 days, whereas normalization of WBC was seen in the mice receiving 5 to 10 X lo5 BM cells. In all groups, treatment by rhIL-6 produced a statistically significant increase in WBC at days 8 and 14 (Table 1) . The overall average effect of rhIL-6 on WBC levels was an in- BALB/c mice subjected to TB1 and syngeneic BMT were treated for 10 days after BMT with rhlL-6 (10 sg/d subcutaneous) or with PBS. Mice were bled at indicated days after BMT. Mean WBC counts k standard deviation are shown.
Abbreviation: N. number of mice for each determination.
crease of 1.56--t 0.15-fold. Elevations of WBC in response to rhIL-6 were seen 8 and 14 days post-BMT at each level of BM cells tested (from 0.5 to 10 X lo5 cells/recipient). At day 14, the increase ranged from 2. l-fold at the lowest BM cell dose to 1.3-fold at the highest dose. Therefore, rhIL-6 has a beneficial effect on WBC reconstitution that was seen even in mice receiving doses of BM cells sufficient to yield quasicomplete survival by themselves. A similar syngeneic BMT experiment was performed after TB1 at 650 cGy. Survival and WBC and platelet reconstitution was observed in five groups (each of 18 BALB/c mice) receiving, respectively, 0.1, 0.5, 2.5, 12.5, or 62.5 X lo5 BM cells. In each group, half of the mice received rhIL-6 at 10 pglday divided in two subcutaneous injections for 10 days and half received identical schedules of PBS injections. As before, increased survival of the IL-6-treated animals was observed at the lower BM cell doses, in this case up to 2.5 X IO5 BM cells (not shown). Platelets were measured at day 10 after BMT and initiation of treatment. IL-6 produced increases in platelet counts, which became statistically significant at the higher doses of BM cells (Table 2 ). In general, platelet recovery at day 10 depended on high BM cell inocula. The highest increase in platelets produced by rhIL-6 was 1 .%fold (P < .OO 1) and was observed at the highest dose of 62.5 X lo5 BM cells, allowing for quasinormalization of platelets. At the same BM cell dose, the WBC counts per milliliter on day 10 were 2.07 X IO6 -+ 0.38 in the controls versus 3.28 X lo6 -+ 0.8 in the IL-6-treated mice, or a 1.6-fold increase in WBC recovery by rhIL-6 (P < .005).
This experiment indicates that normalization ofplatelet values at day 10 after lethal irradiation and BMT is clearly accelerated by rhIL-6, but is dependent on a high BM cell dose.
Eflect of rhIL-6 on engraftment of semiallogeneic BM BALB/c mice were subjected to lethal irradiation (TB1 dose 650 cGy) followed by syngeneic BMT with indicated numbers of BALB/c BM cells. In each group, 9 mice were treated with rhlL-6 (with two subcutaneous injections of 5 pg each day for 10 days) and 9 mice were similarly injected with PBS (control). Mean platelet counts k standard deviation are shown at day 10 after BMT and initiation of treatment.
Abbreviation: NS, not significant.
cells. The effects of 10 days of rhIL-6 treatment on engraftment of F1 mice BM cells in lethally irradiated BALB/ c recipients was investigated, as well as the possibility that enhancement of residual host hematopoietic and immune cells by rhIL-6 may affect such semiallogeneic engraftment.
To measure the effect of rhIL-6 on survival and blood cells counts, 72 BALB/c mice were irradiated at 625 cGy and reconstituted after 20 hours by 1, 5, 25, and 110 X lo5 F1 BM cells per recipient. In each group, 8 mice received rhIL-6 10 pg in one subcutaneous injection per day for 10 consecutive days; 8 mice received similar PBS injections, but no BM cells, serving as irradiated controls. At the two lower doses of F1 BM cells, the death of the semiallogeneic BMT control mice not treated by rhIL-6 was even faster than that of the irradiated controls with no BMT (Fig 2A and B) . Under these conditions, rhIL-6 injections improved survival, particularly at 5 X lo5 F1 BM cells (Fig 2B) , showing an increase in survival rate (P < .007 by log-rank test and generalized Wilcoxon test) and a long-term survival of more than 50% at 1 month, when all mice not treated by IL-6 died by 10 days. A smaller but still significant increase in survival rate by rhIL-6 (P < .03) was also seen at 1 X lo' F1 BM cells (Fig 2A) . At the higher doses of BM cells, survival of the BMT controls was prolonged as compared with that of lower BM cell doses, and no effect of rhIL-6 was observed (Fig 2D) . Thus, at 2.5 x lo6 BM cells, the IL-6-treated mice died as did the controls in 28 to 35 days (Fig 2C) . At 1.1 X lo7 BM cells, 83% of the mice survived at 35 days, versus 7 1% in the IL-6-treated group; thereafter, the mice in both groups died between 50 and 100 days (not shown). Thus, in this model of semiallogeneic BMT, a marked effect of rhIL-6 on survival was again evident under limiting numbers of BM cells, whereas at higher BM cell doses the beneficial effect of IL-6 was lost. In this experiment, the WBC and platelet counts were assessed at day 9 after BMT. Only a trend toward higher platelet and WBC values could be observed with rhIL-6 ( Table 3) , with the actual hematologic recovery being very dependent on the dose of semiallogeneic BM cells infused.
We examined whether rhIL-6 alters the degree of chimerism in BALB/c recipients 6 weeks after lethal irradiation and reconstitution with lo7 F1 BM cells. Chimerism expressed as a percentage of donor-type cells in the peripheral blood was measured in two groups of mice subjected to TB1 at 600 ( 16 mice) or 700 cGy (22 mice), with half of the mice receiving rhIL-6 at 10 pg/d subcutaneously for 10 days and half receiving PBS. The results of both experiments showed equal proportion of chimerism in the rhIL-6 group (mean, 77% ? 9%; median, 80%; range, 66% to 95%) as in the PBS For personal use only. on October 3, 2017. by guest www.bloodjournal.org From group (mean, 73% ? 20%; median, 78%; range, 38% to 95%). These data indicate that engraftment was not impaired by rhIL-6 treatment, with the percentage of donortype (C57BL/6) blood cells being, if anything, higher in the rhIL-6-treated chimeric mice.
Effect of rIL-6 on GVHD and cell-mediated immunologic competence. GVHD was induced in lethally irradiated (750 cGy) F1 mice (H-zdm) inoculated with 2 X IO7 BM cells supplemented with 5 X lo6 spleen cells (20% mixture), both obtained from C57BL/6 donors (H-2b). The spleen cell suspension contained 35% T cells. rhIL-6 at 10 pg/d was administered subcutaneously for 25 days (8 mice); controls received PBS (7 mice) or neither BM nor spleen cells (5 mice).
Body weight loss, mucosal inflammations, ruffled fur, and diarrhea indicated development of GVHD. As shown in Fig  3A and C, the mice treated by rhIL-6 showed a more severe weight loss than the PBS-treated controls (P < .W2 by paired t-test) and mortality was also accelerated (P = .04 by Wilcoxon, and P < .02 by log-rank test). Increased GVHD was also seen in a second experiment (Fig 3B and D) in which the F1 mice received a 2 X IO7 cell mixture of 50% BM cells and 50% spleen cells from C57BL/6 donors, with a 5-day treatment by rhIL-6 (8 mice) or PBS treatment (8 mice) . Mice with GVHD receiving rhIL-6 again showed more weight loss (although statistical significance was not reached, P = .07) and increased mortality (P = .04 by Wilcoxon and P < .03 by log-rank test).
The effect of rhIL-6 treatment on reconstitution of cellmediated immune response was tested in vitro with spleen cells from BALB/c mice 14 or 32 days after syngeneic BMT in an MLR against irradiated C57BL/6 spleen cells (Table  4 ). rhIL-6 administered for 10 days after BMT ( 10 pg/d to 2 mice/group) produced no significant increase or decrease of the proliferative response in MLR. There were also no meaningful changes in the T-cell-dependent proliferative response to mitogens (ConA and PHA) or in B-cell-dependent proliferation in response to LPS ( Table 4) .
Effect of rhIL-6 in sublethally irradiated mice without BMT. The preceding experiments show that rhIL-6 increases survival of irradiated mice receiving limiting amounts of BM cells. It was important to examine whether BALB/c mice were subjected to TBI, reconstituted with (BALB/c x C57BL/6)F1 BM cells, and treated with rhlL-6 or PBS as in Fig 2. The mean WBC and platelet counts were assessed in 5 mice at day 9 of treatment. Significance could not be established.
rhIL-6 treatment may improve the resistance of mice to irradiation without BMT when administered after or before irradiation. In a first experiment with BALB/c mice subjected to sublethal irradiation (550 Gy), the 8 mice receiving injections of rhIL-6 10 pg/d for 9 days after TB1 had decreased survival rates (P = .02) compared with 6 control mice (Fig 4A) . However, when mice were subjected to lethal TB1 (600 cGy), the mortality rate was the same (P = .85) with or without IL-6 (Fig 4B) , ie, rhIL-6 did not show nonspecific toxicity. In a third experimental setting, rhIL-6 was administered as pretreatment 5 days before a TB1 dose of 600 cGY, which in this experiment had a sublethal effect (Fig 4C) . It can be seen that pretreatment by rhIL-6 also accelerated the mortality rate (P = .05) of these irradiated mice deprived of BM cell transplantation.
DISCUSSION
Beneficial effects of rhIL-6 treatment for 10 days after BMT were observed in enhancing the reconstitution of WBC count as well as in enhancing reconstitution of platelets in lethally irradiated mice receiving BMT. Such effects on recovery of platelet production would be of paramount importance in view of the fact that late reconstitution of platelets often represents the single major obstacle particularly after autologous BMT in humans, especially in patients with acute myeloid l e~k e m i a .~~.~~ The accelerated recovery of WBC count and platelets in mice subjected to BMT and treated by rhIL-6 probably reflects the effect of this cytokine on maturation of myeloid cells" and of megakaryocyte^.'^ There may also be an effect on early progenitor cell^,^-^ but it is unlikely that IL-6 would act identically on all hematopoietic lineages. IL-6 has many activities besides hematopoiesis. Because of IL-6's effects on the acute-phase response, on immune functions, and on other physiopathologic p r o c e s s e~,~*~~.~~ it was important to evaluate its impact on BMT not only by hematologic parameters but by overall survival.
In evaluating the survival, we found that, in BALB/c mice not receiving BMT, injections of rhIL-6 either before or after sublethal irradiation tended to increase mortality. The effects of IL-6 on radiation resistance in mice appear to be complex. Thus, Neta et alZ7 observed radiosensitization when IL-6 was injected to mice by itself, but radioprotection when IL-6 was administered with IL-1; conversely, anti-IL-6 antibodies, as well as antibodies blocking IL-1 or TNF actions, markedly reduced the resistance of mice to radiation, indicating that IL-6, along with IL-1 and TNF, plays a role in radioresistance.28 The increased radiosensitivity seen here in mice receiving rhIL-6 without BMT may be caused by an imbalance between the various cytokines, affecting inflammatory processes after sublethal irradiation. It could also indicate that this cytokine stimulates the entry of hematopoietic stem cells into a more radiosensitive cell cycle phase, an effect that might provide a rationale for better eradication of malignant cell precursors. However, it should be noted that, with optimal irradiation, rhIL-6 did not increase the rate of death and appeared devoid of toxic effects, as found in other s t~d i e s .~~,~~ The rhIL-6 used here showed no adverse reactions in baboons subjected to radiation-induced BM depression, in which it clearly accelerated platelet recovery. 23 In any event, the fact that, in the present murine model, rhIL-6 alone was rather radiosensitized, serves to stress the significance of the increased survival produced by rhIL6 injections administered in conjunction with BMT. Indeed, in mice reconstituted by syngeneic BM cells (similar to human autologous BMT), rhIL-6 led to marked increases in survival rates under conditions of limiting BM cells, when mortality is high in untreated controls. In the semiallogeneic BMT model, rhIL-6 again increased survival in mice receiving limited doses of BM cells (5 X lo5), although the beneficial effect was lost at higher doses of allogeneic BM cells (2.5 X lo6). Several parameters of allogeneic BMT were investigated. Our data indicate that rhIL-6 did not impair engraftment or degree of chimerism. This implies that IL-6 does not favor reconstitution of possibly residual host stem cells or residual host T lymphocytes capable of inducing allograft rejection. However, administration of rhIL-6 after allogeneic BMT under conditions inducing GVHD (injection of mature splenocytes with the BM cells) enhanced the manifestations of GVHD assessed by symptomatology as well as by objective parameters such as more severe weight loss and earlier mortality. Such early mortality was not observed in rhIL-6-treated mice receiving allogeneic BM cells without splenocytes. Considering the beneficial effect of rhIL-6 observed under certain conditions of semiallogeneic BMT versus the increased GVHD, it would seem advisable to contemplate the use of rhIL-6 in clinical allogeneic BMT only under conditions in which GVHD can be adequately controlled (eg, by T-cell depletion). The mechanism by which IL-6 enhances GVHD is unclear. Despite the fact that IG6 acts as a helper factor for cytotoxic T-cell (CTL) func- Spleen cells from BALB/c mice subjected to TB1 and syngeneic BMT were tested by one-way MLR against irradiated C57BL/6 spleen cells or in response to indicated mitogen. The percentage of reconstitution of prolierative response eH-thymidine incorporation) was calculated relative to spleen cells of normal mice as described in Materials and Methods. Triplicate values were used to calculate the mean reconstitution k standard deviation for unpaired data. ti on^,^^,^^ our data did not show an increase in T-(or B-) cell-dependent proliferative responses to allogeneic splenocytes or mitogens in spleen cells of mice treated by rhIL-6 after BMT. rhIL-6 also does not increase the number of lymphocytes in normal or BM transplanted m i~e . '~,~~ Because GVHD may be observed also in syngeneic or autologous BMT,'.38 different mechanisms than classical T-celldependent immune responses may be operating in GVHD involving monocytes, natural killer cells, or other cytokinemediated inflammatory processes on which IL-6 may have an effect.
In evaluating the potential significance of the effect of rhIL-6 on GVHD for clinical applications, it is of interest that a direct relationship between GVHD and antileukemic effects exerted by marrow allografts (graft-versus-leukemia [GVL] ) is generally In attempts to modulate the GVL reaction in parallel to GVHD (or preferably independently from it), there may be interesting possibilities for the use of IL-6 in conjunction with allogeneic BMT for immunotherapy of certain malignancies. An antitumoral action of rhIL-6 has been observed in various murine models of erythr~leukemia,~' acute myeloid leukemia,36 metastatic carcinomas, sarcomas, and melanoma.35339 These therapeutic effects were correlated with increased CTL activities against the tumor cells even when poorly immunogenic. Regarding tumor cell growth, IL-6 may have opposite effects, eg, inhibiting myeloid leukemia cells'2-L6 and breast carcinoma cells,7s39 but stimulating growth of malignant B cells such as myelomas,24 some lymphomas (but not B-CLL), and Kaposi sarcoma cells.39 At least in cancer patients in whom IL-6 does not act as tumor cell growth factor (eg, AML, B-CLL, and solid metastatic tumors), the combined activities of IL-6 in enhancing recovery from BMT and in inducing host-mediated antitumoral effects may be of interest in patients subjected to high-dose radiochemotherapy associated with BMT for treatment of their malignant disorder, particularly at the stage of minimal residual disease.' Finally, it may also be worthwhile to investigate whether the sensitizing effect of rhIL-6 to suboptimal TB1 discussed above may contribute to myeloablative therapy in the treatment of malignancies by radiochemotherapy in conjunction with BMT.
In line with the results of Okano et a12' with bacterial rIL-6, we show here that rhIL-6 from C H 0 cells improves survival and WBC reconstitution after syngeneic BMT. Of particular interest is the documented effect of IL-6 therapy on platelet production observed previously in normal and irradiated rodents and primate^^'-^^ and extended here to BMT recipients. IL-6 was shown to act as a direct promoter of megakaryocyte maturation." The fact that in our study of BMT recipients the platelet increase by rhIL-6 was mainly seen with large BM inocula, although rhIL-6 improved survival with suboptimal BM inocula, may also indicate that rhIL-6 acted through committed megakaryocyte platelet progenitors rather than by triggering differentiation of uncommitted cells into the megakaryocytic lineage. The present study shows the potential benefits and the possible limitations of rhIL-6 in syngeneic (autologous) and in allogeneic BMT; it supports the use of this cytokine among the acceptable hematopoietic factors used for improving the efficacy and therapeutic benefits of clinical BMT.'
